HGH vs Peptide Secretagogues: CJC-1295, Ipamorelin & Tesamorelin Research Guide

Growth hormone secretagogues (GHS) are peptides that stimulate the pituitary gland to produce and release endogenous growth hormone (GH), rather than supplying GH directly. The two principal secretagogue classes studied in research are:

• GHRH analogues, mimic growth hormone-releasing hormone (GHRH), binding to GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and release. Examples: CJC-1295, Tesamorelin, Sermorelin.
• GHRPs (Growth Hormone-Releasing Peptides), bind ghrelin receptors (GHS-R1a), synergistically amplifying GH pulses when combined with GHRH analogues. Examples: Ipamorelin, GHRP-2, GHRP-6.

Exogenous recombinant human growth hormone (rhGH), by contrast, bypasses the pituitary entirely, delivering pre-formed GH directly into circulation, suppressing the feedback loop that normally regulates endogenous GH production.

The fundamental pharmacological distinction between direct HGH and secretagogues has significant implications for research design:

CJC-1295 is a synthetic analogue of GHRH with a drug affinity complex (DAC) that binds to albumin after injection, extending its half-life from minutes (native GHRH) to approximately 6–8 days. This produces sustained elevation of GH and IGF-1 rather than the sharp peak-and-trough pattern of short-acting GHRH peptides.

A key clinical study by Teichman et al. (2006) demonstrated that CJC-1295 produced dose-dependent increases in mean plasma GH concentrations (1.5–3-fold above baseline) and IGF-1 levels (1.3–1.9-fold) persisting for 14 days after a single injection. The half-life was approximately 5.8–8.1 days across dose groups.

In research contexts, CJC-1295 is frequently paired with Ipamorelin (a GHRP) to exploit their synergistic action: CJC-1295 elevates the GH pulse amplitude while Ipamorelin amplifies pulse frequency via ghrelin receptor activation.

Ipamorelin is a pentapeptide GHRP that selectively binds the GHS-R1a ghrelin receptor on pituitary somatotrophs, stimulating GH release without meaningfully elevating cortisol or prolactin, a selectivity advantage over earlier GHRPs such as GHRP-2 or GHRP-6.

Research in animal models (Raun et al., 1998) demonstrated that Ipamorelin produced GH release comparable to GHRP-6 but with significantly lower cortisol and ACTH responses. This selective profile makes it a useful research tool for isolating GH axis effects.

The half-life of Ipamorelin is short (~2 hours), meaning research protocols typically involve twice-daily or three-times-daily administration to maintain elevated GH pulses, in contrast to the once-weekly dosing profile of CJC-1295 (DAC).

Tesamorelin (TH9507) is a GHRH analogue stabilised with trans-3-hexenoic acid, extending its half-life to approximately 26 minutes (versus ~7 minutes for native GHRH). It is the only GHRH analogue with FDA approval, specifically for HIV-associated lipodystrophy, providing a robust clinical evidence base relative to other research peptides.

Phase 3 clinical trials (Falutz et al., 2007, 2010) demonstrated that Tesamorelin reduced visceral adipose tissue (VAT) by approximately 15–18% versus placebo over 26 weeks, with statistically significant improvements in trunk fat, triglycerides, and IGF-1 levels. Importantly, these metabolic effects were largely sustained only during active administration, VAT returned toward baseline after cessation.

Unlike CJC-1295, Tesamorelin's shorter half-life requires daily subcutaneous administration in research protocols, but its clinical validation provides higher-quality pharmacokinetic and safety data to draw upon.

Recombinant human growth hormone (rhGH) is the 191-amino-acid protein identical in sequence to endogenous GH, produced via recombinant DNA technology. It acts directly on GH receptors in peripheral tissues and the liver, stimulating IGF-1 production without requiring an intact pituitary axis.

Because exogenous HGH bypasses the hypothalamic-pituitary feedback loop, it produces non-pulsatile, supraphysiological GH concentrations that suppress endogenous GH secretion via somatostatin feedback during administration. This is a key mechanistic distinction from secretagogues, which preserve physiological pulsatility by working upstream.

In research, HGH is used to study direct GH effects on body composition, bone density, protein synthesis, and IGF-1 signalling. OzPeps stocks research-grade HGH in multiple kit configurations: 10IU × 10 vials (100IU), 24IU × 10 vials (240IU), and 40IU × 10 vials (400IU).

The choice between exogenous HGH and peptide secretagogues in a research context depends on the specific question being investigated:

• Studying pituitary-independent GH effects, exogenous HGH is appropriate, as it delivers GH regardless of pituitary status
• Studying physiological GH pulse patterns, GHRH/GHRP combinations (CJC-1295 + Ipamorelin) preserve natural pulsatility, more closely mimicking endogenous secretion
• Studying visceral fat reduction, Tesamorelin has the strongest clinical evidence base for this specific endpoint (FDA approval + Phase 3 RCT data)
• Studying selectivity of GH axis activation, Ipamorelin's clean cortisol/prolactin profile makes it preferred for isolating GH-specific responses
• Long-duration protocols requiring infrequent dosing, CJC-1295 DAC's ~7-day half-life makes it logistically practical

All these compounds are supplied as lyophilised powder requiring reconstitution with bacteriostatic water. Standard protocols:

• HGH, typically reconstituted with 1–2mL bacteriostatic water; store at 2–8°C after reconstitution; use within 14–21 days; avoid agitation when mixing
• CJC-1295, reconstitute with 1–2mL bacteriostatic water; store at 2–8°C; stable for 28–42 days reconstituted
• Ipamorelin, reconstitute with 1–2mL bacteriostatic water; store at 2–8°C; stable for 28–42 days reconstituted
• Tesamorelin, reconstitute with sterile or bacteriostatic water; store at 2–8°C; use within 28 days

All lyophilised peptides store at −20°C for 12–24 months prior to reconstitution. See the full peptide reconstitution guide → or the reconstitution calculator →.

OzPeps stocks research-grade HGH, CJC-1295, Ipamorelin, and Tesamorelin from Australian domestic stock, no international shipping delays or customs complications. All compounds are supplied for in-vitro laboratory and research use only.

• HGH 100IU Kit →
• HGH 400IU Kit →
• CJC-1295 + Ipamorelin 10mg →
• CJC-1295 10mg →
• Ipamorelin 10mg →
• Tesamorelin 10mg →

All compounds discussed are supplied strictly for in-vitro laboratory and scientific research purposes. Not TGA-approved for human use. Not for human or animal consumption. Researchers are responsible for all applicable regulatory compliance in their jurisdiction.